Literature DB >> 10637511

The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties.

A Bertolotti1, B Bell, L Tora.   

Abstract

In Ewing tumor, the (11;22) chromosomal translocation produces a chimeric molecule composed of the amino-terminal domain of EWS fused to the carboxyl-terminal DNA-binding domain of FLI-1. Previously, we have identified a novel protein TAFII68, which is highly similar to EWS and another closely related protein TLS (also called FUS). We demonstrate that the N-terminus of TAFII68 efficiently stimulates transcription when fused to two different DNA binding domains and that overexpression of TAFII68-FLI-1 chimeras in NIH3T3 cells leads to oncogenic transformation. We have also investigated the molecular mechanisms which could account for the transcriptional activation and the oncogenic transformation potential of the N-termini of TAFII68 and EWS. Thus, we have tested whether the artificial recruitment of components of the preinitiation complex (PIC) or a histone acetyltransferase (HAT) could bypass the requirement for the activation domains of either EWS or TAFII68. Recruitment of individual components of the transcription machinery or the GCN5 HAT is not sufficient to promote activation from FLI-1 responsive genes either in transfection experiments or in oncogenic transformation assays. These results suggest that the TAFII68 or EWS activation domains enhance a step after PIC formation in the transcriptional activation process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10637511     DOI: 10.1038/sj.onc.1203207

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Ewing sarcoma gene Ews regulates hematopoietic stem cell senescence.

Authors:  Joonseok Cho; Hongmei Shen; Hui Yu; Hongjie Li; Tao Cheng; Sean Bong Lee; Byeong Chel Lee
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 2.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

3.  Identification of a self-association domain in the Ewing's sarcoma protein: a novel function for arginine-glycine-glycine rich motifs?

Authors:  Debra J Shaw; Robert Morse; Adrian G Todd; Paul Eggleton; Christian L Lorson; Philip J Young
Journal:  J Biochem       Date:  2010-03-07       Impact factor: 3.387

Review 4.  Misregulated RNA processing in amyotrophic lateral sclerosis.

Authors:  Magdalini Polymenidou; Clotilde Lagier-Tourenne; Kasey R Hutt; C Frank Bennett; Don W Cleveland; Gene W Yeo
Journal:  Brain Res       Date:  2012-03-03       Impact factor: 3.252

5.  RGG boxes within the TET/FET family of RNA-binding proteins are functionally distinct.

Authors:  Bess Ling Chau; King Pan Ng; Kim K C Li; Kevin A W Lee
Journal:  Transcription       Date:  2016-05-09

Review 6.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

7.  TLS inhibits RNA polymerase III transcription.

Authors:  Adelene Y Tan; James L Manley
Journal:  Mol Cell Biol       Date:  2010-01       Impact factor: 4.272

8.  Selective interactions of hnRNP M isoforms with the TET proteins TAF15 and TLS/FUS.

Authors:  Marija Marko; Michael Leichter; Meropi Patrinou-Georgoula; Apostolia Guialis
Journal:  Mol Biol Rep       Date:  2014-01-29       Impact factor: 2.316

9.  Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains.

Authors:  Ilmin Kwon; Masato Kato; Siheng Xiang; Leeju Wu; Pano Theodoropoulos; Hamid Mirzaei; Tina Han; Shanhai Xie; Jeffry L Corden; Steven L McKnight
Journal:  Cell       Date:  2013-11-21       Impact factor: 41.582

10.  Human U1 snRNA forms a new chromatin-associated snRNP with TAF15.

Authors:  Laure Jobert; Natalia Pinzón; Elodie Van Herreweghe; Beáta E Jády; Apostolia Guialis; Tamás Kiss; László Tora
Journal:  EMBO Rep       Date:  2009-03-13       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.